CYRX
Cryoport, Inc.9.24
+0.00+0%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
462.64MP/E (TTM)
-Basic EPS (TTM)
-1.22Dividend Yield
0%Recent Filings
8-K
Cryoport Q3 revenue surges 15%
Cryoport reported Q3 2025 revenue of $44.2 million, up 15% year-over-year, driven by 36% growth in commercial cell and gene therapy support to $8.3 million and 16% rise in Life Sciences Services. Gross margin expanded to 48.2%, while adjusted EBITDA improved to a negative $0.6 million. The company raised full-year revenue guidance to $170-$174 million, bolstered by new Paris facility and DHL partnership. Momentum builds, yet U.S. government shutdown risks approvals.
10-Q
Q2 FY2025 results
Cryoport's Q2 FY2025 revenue climbed 14.5% y/y to $45.5M, with Life Sciences Services up 20.9% y/y on strong BioLogistics demand, while Products grew 7.8% y/y; gross margin expanded to 47.0% from 44.5%, yet operating loss narrowed to $9.6M from $78.0M after stripping out last year's impairment. Q/q, revenue rose 9.1% (derived) from Q1's $40.9M, reflecting steady momentum in cell and gene therapy support for 728 trials. The June 11, 2025 CRYOPDP divestiture to DHL fetched $133.0M cash plus $77.2M loan repayment, recognizing a $116.7M gain in discontinued ops and boosting cash to $243.4M with $182.6M in short-term investments; total debt sits at $186.2M in 2026 notes. Free cash flow from continuing ops was negative $19.2M (derived, operating cash -$11.7M minus $7.5M capex). Diluted EPS of $2.05 reconciles to 50.3M shares, though anti-dilution from preferred and notes excluded 9.5M shares. Competition in biologistics remains a key risk.
8-K
Q2 revenue up 14% to $45.5M
Cryoport reported Q2 2025 revenue of $45.5 million, up 14% year-over-year, driven by 21% growth in Life Sciences Services to $24.4 million and 33% surge in commercial cell and gene therapy support to $8.7 million. The company closed its CRYOPDP divestiture to DHL on June 11, 2025, forging a strategic partnership that bolsters global reach in EMEA and APAC while injecting capital. Gross margins expanded to 47.0%, adjusted EBITDA improved to negative $0.9 million, and full-year revenue guidance holds at $165-172 million. Revenue climbed steadily.
8-K
CRYOPDP sale to DHL closes
Cryoport completed the sale of its CRYOPDP specialty courier business to DHL affiliates on June 11, 2025, for $133 million in cash plus $77.2 million in intercompany loan repayments. This divestiture sharpens focus on regenerative medicine services while launching a strategic partnership to bolster APAC and EMEA reach through DHL's logistics muscle. Cash bolsters the balance sheet. Pro forma results show reduced losses, yet integration costs loom.
8-K
Cryoport annual meeting results
Cryoport, Inc. held its 2025 Annual Meeting on June 6, electing six directors—Linda Baddour, Daniel M. Hancock, Robert Hariri, Ram M. Jagannath, Ramkumar Mandalam, and Jerrell W. Shelton—with strong support exceeding 90% for most nominees. Shareholders ratified Deloitte & Touche as auditors and approved executive compensation via advisory vote. The board will hold annual say-on-pay votes. Continuity strengthens governance amid withheld votes on select directors.
IPO
Website
Employees
Sector
Industry
BLFS
BioLife Solutions, Inc.
24.61-0.04
CCEL
Cryo-Cell International, Inc.
3.80+0.06
CHRW
C.H. Robinson Worldwide, Inc.
159.04+1.43
CJMB
Callan JMB Inc.
1.77+0.06
CRGO
Freightos Limited
3.06-0.01
EXPD
Expeditors International of Was
149.98-1.59
GXO
GXO Logistics, Inc.
52.61+0.27
JANL
Janel Corp.
34.00+0.00
LSTR
Landstar System, Inc.
144.57-1.78
RSCF
Reflect Scientific, Inc.
0.05+0.00